A single blind randomised active-controlled Phase-III study to evaluate immunogenicity, safety, tolerability of a candidate 14-valent pneumococcal polysaccharide conjugate vaccine administered to 6-8 weeks old healthy Indian Infants in 6-10-14 weeks dosing schedule. - None
Latest Information Update: 18 Jun 2020
Price :
$35 *
At a glance
- Drugs Pneumococcal conjugate vaccine 14-valent - Biological E Limited (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Biological E Limited
- 18 Jun 2020 New trial record